title: Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.
abstract: Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Conventional treatment options have limited efficacy because most cases are in the advanced stage at the time of diagnosis. In recent years, gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown its good antitumor activities in treating NSCLC in a number of studies. This paper reviews its role in the targeted treatment of NSCLC in Chinese patients.
authors.affiliation: Department of Oncology, Center of Oncology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
authors.forename: Meng-Jiao
authors.initials: MJ
authors.lastname: Li
authors.affiliation: Department of Oncology, Center of Oncology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
authors.forename: Qing
authors.initials: Q
authors.lastname: He
authors.affiliation: Department of Oncology, Center of Oncology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
authors.forename: Mei
authors.initials: M
authors.lastname: Li
authors.affiliation: Department of Oncology, Center of Oncology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
authors.forename: Feng
authors.initials: F
authors.lastname: Luo
authors.affiliation: Department of Oncology, Center of Oncology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
authors.forename: Yong-Song
authors.initials: YS
authors.lastname: Guan
keywords: EGFR-TK inhibitor; People’s Republic of China; pulmonary carcinoma; status; therapy